Pub Date : 2022-01-01DOI: 10.1615/oncotherap.2022045072
G. Nagaraju
{"title":"Citrus flavones Luteolin and Apigenin: targets fundamental mechanisms in colon cancer","authors":"G. Nagaraju","doi":"10.1615/oncotherap.2022045072","DOIUrl":"https://doi.org/10.1615/oncotherap.2022045072","url":null,"abstract":"","PeriodicalId":74340,"journal":{"name":"Onco therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76840498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1615/oncotherap.2022042541
C. Kieda, Kinga Wilkus, C. Szczylik
{"title":"Microenvironment-dependent endothelial cells glycosylation influence on angiogenesis and cancer spreading","authors":"C. Kieda, Kinga Wilkus, C. Szczylik","doi":"10.1615/oncotherap.2022042541","DOIUrl":"https://doi.org/10.1615/oncotherap.2022042541","url":null,"abstract":"","PeriodicalId":74340,"journal":{"name":"Onco therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88590260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1615/oncotherap.2022044866
R. Malla, K. Patnala, Mini Fernandez
{"title":"Novel and latest computational routes for design and development of anticancer drugs for colon cancer","authors":"R. Malla, K. Patnala, Mini Fernandez","doi":"10.1615/oncotherap.2022044866","DOIUrl":"https://doi.org/10.1615/oncotherap.2022044866","url":null,"abstract":"","PeriodicalId":74340,"journal":{"name":"Onco therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86326749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1615/oncotherap.2022044893
Sarojamma Vemula, Ramakrishna Vadde
{"title":"Naringenin in the prevention of colon cancer – An updated review","authors":"Sarojamma Vemula, Ramakrishna Vadde","doi":"10.1615/oncotherap.2022044893","DOIUrl":"https://doi.org/10.1615/oncotherap.2022044893","url":null,"abstract":"","PeriodicalId":74340,"journal":{"name":"Onco therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89080420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1615/oncotherap.2022044943
G. Nagaraju
{"title":"Phytochemicals for colorectal cancer therapy","authors":"G. Nagaraju","doi":"10.1615/oncotherap.2022044943","DOIUrl":"https://doi.org/10.1615/oncotherap.2022044943","url":null,"abstract":"","PeriodicalId":74340,"journal":{"name":"Onco therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72714107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1615/oncotherap.v9.i2.10
Ganji Ganji
{"title":"Preface: Phytochemicals for Colorectal Cancer Therapy","authors":"Ganji Ganji","doi":"10.1615/oncotherap.v9.i2.10","DOIUrl":"https://doi.org/10.1615/oncotherap.v9.i2.10","url":null,"abstract":"","PeriodicalId":74340,"journal":{"name":"Onco therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73590297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1615/oncotherap.2022045040
Andrea Cedillo Ornelas, Sam Ferguson, Maya DePlaza, Tkai Adekunle, R. Basha
A class of plant polysaccharides, pectin is known to display several medicinal properties including in cancer. There is some evidence that pectin from some fruits can reduce the severity of colorectal cancer (CRC) due to its antiproliferative, anti-inflammatory, antimetastatic and pro-apoptotic properties. Pectin fermentation in the colon induces antiproliferative activity via butyrate. Research also showed that pectin acts as a potent inducer of programmed cell death and cell-cycle arrest, thereby selectively targeting cancer cells. Pectin can limit oxidative stress to maintain cellular homeostasis while increasing reactive oxygen species damage to activate cancer cell death. Pectin regulates various signaling cascades, e.g., signal transduction and transcriptional activator and mitogen-activated protein kinase signaling, that contribute to its anticancer activity. By curbing inflammation-activated signaling and bolstering immune-protective mechanisms pectin can eradicate CRC. Due to its chemical structure, pectin can also inhibit galectin-3 and suppress tumor growth and metastasis. Prior reports also suggested that pectin is beneficial to use alongside the CRC standard care. Pectin can increase sensitivity to conventional CRC drugs, alleviate unwanted side effects and reduce drug resistance. Although some preclinical studies are promising, early clinical trials are showing some evidence for pectin's efficacy in tumor growth inhibition and preventing metastasis in some cancers; however, the clinical use of pectin in CRC therapy is not yet well established. Further studies are needed to confirm the efficacy of pectin treatment as a valid clinical therapy for CRC in humans.
{"title":"Anti-Cancer Pectins and Their Role in Colorectal Cancer Treatment.","authors":"Andrea Cedillo Ornelas, Sam Ferguson, Maya DePlaza, Tkai Adekunle, R. Basha","doi":"10.1615/oncotherap.2022045040","DOIUrl":"https://doi.org/10.1615/oncotherap.2022045040","url":null,"abstract":"A class of plant polysaccharides, pectin is known to display several medicinal properties including in cancer. There is some evidence that pectin from some fruits can reduce the severity of colorectal cancer (CRC) due to its antiproliferative, anti-inflammatory, antimetastatic and pro-apoptotic properties. Pectin fermentation in the colon induces antiproliferative activity via butyrate. Research also showed that pectin acts as a potent inducer of programmed cell death and cell-cycle arrest, thereby selectively targeting cancer cells. Pectin can limit oxidative stress to maintain cellular homeostasis while increasing reactive oxygen species damage to activate cancer cell death. Pectin regulates various signaling cascades, e.g., signal transduction and transcriptional activator and mitogen-activated protein kinase signaling, that contribute to its anticancer activity. By curbing inflammation-activated signaling and bolstering immune-protective mechanisms pectin can eradicate CRC. Due to its chemical structure, pectin can also inhibit galectin-3 and suppress tumor growth and metastasis. Prior reports also suggested that pectin is beneficial to use alongside the CRC standard care. Pectin can increase sensitivity to conventional CRC drugs, alleviate unwanted side effects and reduce drug resistance. Although some preclinical studies are promising, early clinical trials are showing some evidence for pectin's efficacy in tumor growth inhibition and preventing metastasis in some cancers; however, the clinical use of pectin in CRC therapy is not yet well established. Further studies are needed to confirm the efficacy of pectin treatment as a valid clinical therapy for CRC in humans.","PeriodicalId":74340,"journal":{"name":"Onco therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87130397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1615/oncotherap.2022044940
S. Aliya, Y. Huh
{"title":"Nano-formulation for Curcumin and Resveratrol in the Colorectal Cancer Therapy","authors":"S. Aliya, Y. Huh","doi":"10.1615/oncotherap.2022044940","DOIUrl":"https://doi.org/10.1615/oncotherap.2022044940","url":null,"abstract":"","PeriodicalId":74340,"journal":{"name":"Onco therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87531982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1615/OncoTherap.2022044575
Christoffer Lambring, Kelly Varga, Keriman Livingston, Nicholas Lorusso, Amil Dudhia, Riyaz Basha
Curcumin (CUR), a natural phenolic compound, has been increasingly investigated in several malignancies due to its safe profile and ability to affect a wide range of oncogenic targets. With the ability to affect metastasis, apoptosis, and angiogenesis in colorectal cancer (CRC) and its tolerability at high doses, CUR is an attractive target for study. However, poor bioavailability and unfavorable pharmacokinetics and pharmacodynamics have hampered CUR's efficacy in clinical trials. Development of its derivatives and alternative delivery methods have shown the potential to overcome its inherent bioavailability issues. Recent analyses of various derivatives and nanoparticle encapsulation of CUR have demonstrated increased effectiveness in CRC studies. A major advantage of CUR has been its synergistic effects when used in combination with various chemotherapeutic agents. CUR offers a unique treatment option in terms of patient safety and its ability to be used in combination with current treatments for CRC. Further development of its derivatives and alternative delivery options offer potential new avenues of treatment that could outperform previous efforts to establish CUR as a CRC therapy.
姜黄素（CUR）是一种天然酚类化合物，由于其安全的特性和影响多种致癌靶点的能力，在多种恶性肿瘤中的研究越来越多。姜黄素能够影响结直肠癌（CRC）的转移、凋亡和血管生成，而且在高剂量下具有耐受性，因此是一个极具吸引力的研究对象。然而，较差的生物利用度以及不利的药代动力学和药效学影响了 CUR 在临床试验中的疗效。其衍生物和替代给药方法的开发显示出克服其固有的生物利用度问题的潜力。最近对 CUR 的各种衍生物和纳米颗粒封装进行的分析表明，CUR 在 CRC 研究中的有效性有所提高。CUR 的一大优势是与各种化疗药物联合使用时的协同效应。就患者安全性及其与目前治疗 CRC 的药物联合使用的能力而言，CUR 提供了一种独特的治疗选择。进一步开发其衍生物和替代给药方案为治疗提供了潜在的新途径，可能会超越之前将 CUR 确立为 CRC 治疗方法的努力。
{"title":"Therapeutic Applications of Curcumin and Derivatives in Colorectal Cancer.","authors":"Christoffer Lambring, Kelly Varga, Keriman Livingston, Nicholas Lorusso, Amil Dudhia, Riyaz Basha","doi":"10.1615/OncoTherap.2022044575","DOIUrl":"10.1615/OncoTherap.2022044575","url":null,"abstract":"<p><p>Curcumin (CUR), a natural phenolic compound, has been increasingly investigated in several malignancies due to its safe profile and ability to affect a wide range of oncogenic targets. With the ability to affect metastasis, apoptosis, and angiogenesis in colorectal cancer (CRC) and its tolerability at high doses, CUR is an attractive target for study. However, poor bioavailability and unfavorable pharmacokinetics and pharmacodynamics have hampered CUR's efficacy in clinical trials. Development of its derivatives and alternative delivery methods have shown the potential to overcome its inherent bioavailability issues. Recent analyses of various derivatives and nanoparticle encapsulation of CUR have demonstrated increased effectiveness in CRC studies. A major advantage of CUR has been its synergistic effects when used in combination with various chemotherapeutic agents. CUR offers a unique treatment option in terms of patient safety and its ability to be used in combination with current treatments for CRC. Further development of its derivatives and alternative delivery options offer potential new avenues of treatment that could outperform previous efforts to establish CUR as a CRC therapy.</p>","PeriodicalId":74340,"journal":{"name":"Onco therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262216/pdf/nihms-1904401.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10042336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：